Vor Biopharma Inc. $VOR Stock Position Raised by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. grew its stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) by 852.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,617,354 shares of the company’s stock after acquiring an additional 3,237,714 shares during the period. Vor Biopharma accounts for approximately 6.3% of Fcpm Iii Services B.V.’s portfolio, making the stock its 6th largest holding. Fcpm Iii Services B.V. owned 0.35% of Vor Biopharma worth $47,315,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Vor Biopharma during the fourth quarter worth $33,275,000. NEXTBio Capital Management LP bought a new position in Vor Biopharma in the 4th quarter valued at $13,080,000. UBS Group AG boosted its holdings in Vor Biopharma by 284.8% in the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after purchasing an additional 216,209 shares during the period. Jane Street Group LLC bought a new stake in shares of Vor Biopharma during the 1st quarter worth $140,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Vor Biopharma by 578.3% during the 4th quarter. Geode Capital Management LLC now owns 185,808 shares of the company’s stock worth $2,432,000 after acquiring an additional 158,416 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on VOR shares. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush lifted their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Finally, Wells Fargo & Company started coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vor Biopharma presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction on Monday, April 6th. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63. Following the transaction, the director owned 4,555,741 shares in the company, valued at $75,579,743.19. This trade represents a 11.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 3,002,903 shares of company stock valued at $49,412,176. 0.27% of the stock is owned by company insiders.

Vor Biopharma Trading Up 0.3%

Shares of NASDAQ:VOR opened at $14.11 on Wednesday. The company’s fifty day moving average is $14.93 and its 200 day moving average is $14.03. Vor Biopharma Inc. has a 52 week low of $4.06 and a 52 week high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, sell-side analysts forecast that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).